Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy post-menopausal female subjects, at least 45 years of age, with confirmed post-menopausal status~* Hysterectomized subjects~* Body Mass Index (BMI) less than or equal to 34.0 kg/m2~* Nonsmoker or smoker of fewer than 5 cigarettes per day as determined by history~* An informed consent document signed and dated by the subject~Exclusion Criteria:~* History of significant blood, kidney, endocrine, lung, gastrointestinal, heart, liver, psychiatric, neurologic, or allergic disease~* Presence or history of deep vein thrombosis or transient ischemic attack~* History of seizure disorder~* Presence or history of glaucoma or increased intraocular pressure~* Allergy to or unable to tolerate tamoxifen, desvenlafaxine, or venlafaxine~* History of substance abuse within 1 year of study~* A positive urine drug screen~* Treatment with an investigational drug within 30 days~* Consumption of grapefruit or grapefruit related citrus fruits~* 12 lead ECG demonstrating QTc \>450 msec at screening~* Pregnant or nursing females~* Use of prescription or nonprescription drugs and dietary supplements~* History of sensitivity to heparin or heparin induced thrombocytopenia~* Severe acute or chronic medical or psychiatric condition or laboratory abnormality~* Use of CYP 2D6 inhibitors and CYP 3A4 inhibitors/inducers

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tamoxifen and Desvenlafaxine SR (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).